Edward Chait, Ph.D. is Executive Vice President and Chief Scientific Officer of Bioanalytical Systems, Inc. Dr. Chait’s previous assignment was CEO of Spectral Genomics, Inc. Prior to joining Spectral, Dr. Chait was CEO of PharmaCore, Inc., High Point, NC, a small molecule drug discovery company providing molecular building blocks, custom organic synthesis and cGMP services to biotechnology and pharmaceutical companies. Dr. Chait began his career at Du Pont where he held positions of increasing responsibility in R&D, sales and marketing and became Director of Licensing and Acquisition for the Biotechnology and Diagnostic division of the company. In this role, he initiated DuPont’s genetics instruments business and negotiated licenses for DuPont technology with other companies. Earlier, he managed the DuPont mass spectrometer instrument business. After leaving DuPont, Dr. Chait became Senior Vice President, Business and Technology Development at Intergen Company, Purchase, NY. At Intergen, an innovator and manufacturer of biochemicals and research products, he implemented a program of strategic acquisitions, growing Intergen over a decade until it was acquired by Serologicals Corporation. Dr. Chait received a BA degree in Chemistry from Cornell University in 1964 and a Ph.D. in Analytical Chemistry from Purdue University in 1968. He has also served on the Visiting Committee of NIST, the US Israel Technology Commission of the Department of Commerce, and the Advisory Board of the Purdue University Cancer Center.